Abstract: Provided are a lipid and a composition that can effectively deliver an introduction compound such as a nucleic acid to a target cell, tissue, or the like in vivo.

Abstract: Provided is a method for producing a monounsaturated fatty acid having 16 carbon atoms by a method other than chemical synthesis. The method for producing a monounsaturated fatty acid having 16 carbon atoms comprises a step of culturing bacteria of the genus Bifidobacterium capable of producing a monounsaturated fatty acid having 16 carbon atoms in a liquid medium.

Abstract: The present disclosure provides a mutant of rhodopsin and a protein moiety thereof, nucleic acids encoding them, a cell containing any of them, and a method for culturing the cell.

Abstract: The present invention provides a novel elastin production promoter. The elastin production promoter contains sialidase as an active ingredient.

Abstract: A particle includes at least one or more kinds of substrate and lipid nanoparticles. The lipid nanoparticles are dispersed in the substrate and contain a physiologically active substance. The lipid nanoparticles are one or more kinds selected from liposomes, lipid emulsions, and solid lipid nanoparticles. A corresponding powder inhalant contains the particle. A production method for the particle includes granulating and drying, in which a suspension containing the substrate and the lipid nanoparticles are granulated and dried in a gas medium.

Abstract: The present invention relates to a compound represented by the following General Formula (1) or a salt thereof. In General Formula (1), R1, R2, R3 and R4 each independently represent a hydrogen atom, a linear or branched alkyl group which may have a substituent or the like. R1 and R2 may be bonded to each other to form a ring. R3 and R4 may be bonded to each other to form a ring. R1 and/or R2 may be bonded to a 6-membered ring to which —NR1R2 is bonded to form a ring. R3 and/or R4 may be bonded to a 6-membered ring to which —NR3R4 is bonded to form a ring. R5 represents —11CH3, a linear or branched alkyl group which may have a substituent or the like. R6 represents —F, —18F or the like. X, Y and Z each independently represent a carbon atom, an oxygen atom or the like. n is 0 or 1.

Abstract: Provided is a method for efficiently proliferating an influenza virus serving as a material for vaccine in a host. A method for proliferating an influenza virus in a host, comprising a step of inhibiting transfer of Bax in a host cell to the inner mitochondrial membrane.

Abstract: The present invention relates to a solid dispersion containing a compound represented by General Formula (I): wherein R1 is an unsubstituted phenyl group or a phenyl group substituted with a substituent; the substituent is an alkyl group having 1 to 8 carbon atoms, an alkyl group having 1 to 8 carbon atoms substituted with a halogen atom, an alkoxy group having 1 to 8 carbon atoms, an alkoxycarbonyl group having 2 to 8 carbon atoms, a formyl group, a carboxyl group, a halogen atom, a phenyl group or a phenoxy group; R2 is a cyano group or a nitro group; R3 is a hydroxyl group; X is an oxygen atom or —S(O)n—; n is an integer of 0 to 2; Y is an oxygen atom or a sulfur atom, or a pharmaceutically acceptable salt thereof and a hypromellose derivative.

Abstract: An object is to provide a lipid particle that is not positively charged at a pH of the body fluid (typically in the neutral range), and that enables efficient onset of the effect of a medicinal substance encapsulated in the lipid particle; and to provide a lipid for forming the lipid particle. The object is achieved by the phospholipid represented by formula (1), and a lipid particle containing the phospholipid: wherein R1 and R2 are identical or different, and represent a chain hydrocarbon group, m represents 1 or 2, n represents 1 or 2, and p represents an integer of 1 to 4.

Abstract: A method for producing particles, the method including: applying vibration to a liquid including a physiologically active substance and included in a liquid-column resonance liquid-chamber to form a standing wave based on liquid column resonance, to thereby discharge the liquid from at least one discharging port, which is formed in an amplitude direction of the standing wave, to at least one region corresponding to at least one anti-node of the standing wave; and drying the liquid discharged, to thereby form particles.

Abstract: An object is to provide a lipid particle that is not positively charged at a pH of the body fluid (typically in the neutral range), and that enables efficient onset of the effect of a medicinal substance encapsulated in the lipid particle; and to provide a lipid for forming the lipid particle. The object is achieved by the phospholipid represented by formula (1), and a lipid particle containing the phospholipid: wherein R1 and R2 are identical or different, and represent a chain hydrocarbon group, m represents 1 or 2, n represents 1 or 2, and p represents an integer of 1 to 4.

Abstract: A method for producing particles, the method including: applying vibration to a liquid including a physiologically active substance and included in a liquid-column resonance liquid-chamber to form a standing wave based on liquid column resonance, to thereby discharge the liquid from at least one discharging port, which is formed in an amplitude direction of the standing wave, to at least one region corresponding to at least one anti-node of the standing wave; and drying the liquid discharged, to thereby form particles.

Abstract: The method for distinguishing between prostate carcinoma and benign prostatic hyperplasia comprising: bringing an analyte sample containing a prostate-specific antigen (PSA) into contact with a carrier having an anti-free PSA antibody immobilized thereon, thereby binding free PSA to the anti-free PSA antibody immobilized on the carrier; thereafter bringing the carrier in which the free PSA is bound to the immobilized anti-free PSA antibody into contact with a monoclonal antibody capable of specifically recognizing a glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond, thereby binding the monoclonal antibody recognizing the glycan to the free PSA bound to the anti-free PSA antibody; measuring the amount of the free PSA having an N-type glycan in which a terminal sialic acid residue is bound to galactose through an ?(2,3) bond; comparing the measured amount thus obtained with a preset cutoff value for prostate carcinoma and benign prostatic hyperplasia, thereby determinin

Abstract: It is an object to provide a simplified early diagnosis method for breast cancer, wherein a sample collected from a human subject is analyzed and determination of the presence or absence of breast cancer is made from the proportion of plural types of polyamines including N1-acetylspermidine.

Abstract: The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.

Abstract: An object of the present invention is to provide a method for distinguishing between prostate carcinoma and benign prostatic hyperplasia with high sensitivity and good reproducibility using a small amount of an analyte sample.

Abstract: The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.

Abstract: A polymer containing an N-linked sialo-glycan wherein a sialo-glycan is condensed to a ?-polyglutamic acid using a chemical compound having an amino group on one end and a carboxyl group on another end and represented by the structural formula (I). Formula (I) (In the formula, Z means a hydroxy group or a residue represented by the formula (II), and n represents an integer of 10 or more, with the proviso that any one or more of the Z's is represented by the formula in (II).) Formula (II) (In the formula, X means a hydroxy group or an acetylamino group, Y1 and Y2 mean a hydroxyl group or an N-acetylneuraminic acid residue, L means a hydrocarbon, an m represents 0 or an integer of 1 or 2, with the proviso that Y1 and Y2 are not the same.

Abstract: The present invention provides novel phospholipid derivatives. Furthermore, the present invention provides lipid membrane structures excellent in gene/nucleic acid introduction efficiency into a cell.

Abstract: Disclosed is a method for cheaply and easily producing theaflavins. After adding a large quantity of water to raw tea leaves that have not undergone wilt treatment, the tea leaves are crushed in a blender and then let stand, shaken, or agitated, thereby efficiently convening four types of catechins in the raw tea leaves to theaflavins. After adding water and crushing the raw tea leaves, letting the tea leaves stand allows theaflavins to be selectively obtained with high yield. Shaking the raw tea leaves which have had water added and been crushed allows four types of theaflavins to be obtained with high yield. The generated theaflavins can be easily collected using a method such as extraction by organic solvent.